Department of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, United States.
Institute of Immunology, Christian-Albrechts University of Kiel and University Hospital Schleswig-Holstein, Kiel, Germany.
Front Immunol. 2021 Nov 12;12:765906. doi: 10.3389/fimmu.2021.765906. eCollection 2021.
Vitamin C (VitC), in addition to its role as a general antioxidant, has long been considered to possess direct anti-cancer activity at high doses. VitC acts through oxidant and epigenetic mechanisms, which at high doses can exert direct killing of tumor cells and delay tumor growth . Recently, it has also been shown that pharmacologic-dose VitC can contribute to control of tumors by modulating the immune system, and studies have been done interrogating the role of physiologic-dose VitC on novel adoptive cellular therapies (ACTs). In this review, we discuss the effects of VitC on anti-tumor immune cells, as well as the mechanisms underlying those effects. We address important unanswered questions concerning both VitC and ACTs, and outline challenges and opportunities facing the use of VitC in the clinical setting as an adjunct to immune-based anti-cancer therapies.
维生素 C（VitC）除了作为一种一般抗氧化剂的作用外，长期以来一直被认为在高剂量下具有直接的抗癌活性。VitC 通过氧化剂和表观遗传机制起作用，高剂量时可以直接杀死肿瘤细胞并延缓肿瘤生长。最近，也有研究表明，药理剂量的 VitC 通过调节免疫系统有助于控制肿瘤，并且已经进行了研究，以探讨生理剂量的 VitC 对新型过继性细胞疗法（ACTs）的作用。在这篇综述中，我们讨论了 VitC 对抗肿瘤免疫细胞的影响，以及这些影响的潜在机制。我们解决了 VitC 和 ACTs 都存在的一些重要的未解答的问题，并概述了在临床环境中使用 VitC 作为免疫抗癌疗法的辅助手段所面临的挑战和机遇。
